Opinion
Video
Michael Cookson, MD, on potential future applications of PSMA-PET
Author(s):
“In some ways, it can be used to help if you want to get a biopsy to prove or confirm—it can be used to help detect in that range, too,” says Michael S. Cookson, MD, MMHC, FACS.
In this interview, Michael S. Cookson, MD, MMHC, FACS, touches on the current and future applications of PSMA-PET imaging in prostate cancer. Cookson, who is a professor and the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City, is a co–editor in chief for Urology Times.
Video Transcript:
I think about the patients with say, radiation-recurrent disease, we usually get an MRI of their pelvis, and then we get a complimentary PSMA-PET for staging, but it's also showing us disease in the primary as well. In some ways, it can be used to help if you want to get a biopsy to prove or confirm—it can be used to help detect in that range, too. That's a new area. We're not quite to the point—we don't omit the biopsy currently. We still get a piece of tissue from that primary prostate if it does look like it's recurred. But it's starting to be to the point where, when you have an MRI lesion, say, post-radiation, with a rising PSA, and it correlates with the PET scan, then that disease is, for the most part, very real, and it's just confirmed with a biopsy, but you already knew it was there. Stay tuned on that. We're still using tissue to kind of make decisions on treatment in that setting.
This transcript was AI generated and edited by human editors for clarity.
